Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Tanabe Pharma Corporation clinical trials
Also known as Mitsubishi Tanabe Pharma, MTPC.
Part of K.K. BCJ-94.
The registry lists 185 studies whose lead sponsor is Tanabe Pharma Corporation or one of 4 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.
Keep track of what changes. Save the Tanabe Pharma Corporation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Tanabe Pharma Corporation.
- Tanabe Pharma Corporation92 studiesSame company
Something wrong?
- Mitsubishi Tanabe Pharma Corporation40 studiesSame company
Something wrong?
- Medicago18 studies →Acquired — became part of Tanabe Pharma Corporation, Sep 18, 2013 · source ↗
Something wrong?
- NeuroDerm Ltd.14 studies →Acquired — became part of Tanabe Pharma Corporation, Oct 18, 2017 · source ↗
Something wrong?
- Tanabe Pharma America, Inc.13 studies →Regional office
Something wrong?
- Mitsubishi Tanabe Pharma America Inc.7 studies →Regional office
Something wrong?
- Tanabe Pharma GmbH1 studySame company
Something wrong?
Focus areas
Conditions Tanabe Pharma Corporation leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 185. Browse all 185 →
- Study of BK1803 in Healthy InfantsNot yet recruitingNCT07793513Phase 3
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2
Sponsor listed in the registry: Tanabe Pharma America, Inc.
- Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Active, not recruitingNCT05005975Phase 3
Sponsor listed in the registry: Tanabe Pharma America, Inc.
- A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsCompletedNCT01883505Phase 2
Sponsor listed in the registry: NeuroDerm Ltd. · First submitted before NeuroDerm Ltd. became part of Tanabe Pharma Corporation
- A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLActive, not recruitingNCT05658562Phase 1/2
- INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPCompletedNCT06144840Phase 3
Sponsor listed in the registry: Tanabe Pharma America, Inc.
- Effects of Iron Supplements on the Pharmacokinetics of MT-6548CompletedNCT03645863Phase 3
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03329196Phase 3
- Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03402386Phase 3
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03461146Phase 3
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03439137Phase 3
- The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.CompletedNCT06994286Phase 1
- Exploratory Clinical Study of MT-2301CompletedNCT02140047Phase 2
- An Exploratory Study of MT-2990 in Patients With AAVCompletedNCT06196905Phase 1
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenCompletedNCT03291067Phase 2
Sponsor listed in the registry: Tanabe Pharma America, Inc.
- Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsCompletedNCT03541200Phase 2
Sponsor listed in the registry: Tanabe Pharma America, Inc.
- A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With HyperphosphatemiaCompletedNCT00416520Phase 3
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02220920Phase 4
- Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00772382Phase 3
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)CompletedNCT00500682Phase 3
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesCompletedNCT01413204Phase 3
- A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and DyslipidaemiaCompletedNCT00542386Phase 3
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)CompletedNCT00501046Phase 3
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesCompletedNCT01022112Phase 2
- A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With HyperphosphatemiaCompletedNCT00506441Phase 3
- The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisCompletedNCT01861522Phase 3
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedNCT02227849Phase 4
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02622113Phase 4
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01512849Phase 1
- A Clinical Study of Increased Dose of TA-650 in Patients With PsoriasisCompletedNCT01680159Phase 3
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusCompletedNCT01387737Phase 3
- Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic PatientsCompletedNCT00707954Phase 1/2
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic DermatitisCompletedNCT01840605Phase 3
- Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)CompletedNCT00805766Phase 3
- Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy SubjectsCompletedNCT01976572Phase 1
- Clinical Study of TA-650 in Patients With Refractory Kawasaki DiseaseCompletedNCT01596335Phase 3
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)CompletedNCT02354235Phase 3
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)CompletedNCT02354222Phase 3
- Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CCompletedNCT00200343Phase 3
- Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe PainCompletedNCT03245008Phase 2/3
- Clinical Study of TA-650 in Pediatric Patients With Ulcerative ColitisCompletedNCT01585155Phase 3
- Clinical Study of TA-650 in Pediatric Patients With Crohn's DiseaseCompletedNCT01580670Phase 3
- Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special LesionsCompletedNCT01532570Phase 3
- A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisCompletedNCT01425632Phase 3
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on DialysisCompletedNCT00858637Phase 3
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With HyperphosphatemiaCompletedNCT00542815Phase 3
- Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00971243Phase 2
- Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid ArthritisCompletedNCT00691028Phase 3
- A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisCompletedNCT01900054Phase 3
- Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesCompletedNCT02220907Phase 3